Moomoo AI 已提取核心信息
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, completed a sale of 1,913 common shares on February 20, 2024. The transaction was executed at a price of $79.67 per share, resulting in a total market value of $152,408.71. Prior to this sale, Kasinger acquired 3,825 shares through the exercise of derivative securities on February 18, 2024. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics amount to 57,371 common shares. The sale represents an open market transaction, and the acquisition was a result of exercising options available to Kasinger.
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, completed a sale of 1,913 common shares on February 20, 2024. The transaction was executed at a price of $79.67 per share, resulting in a total market value of $152,408.71. Prior to this sale, Kasinger acquired 3,825 shares through the exercise of derivative securities on February 18, 2024. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics amount to 57,371 common shares. The sale represents an open market transaction, and the acquisition was a result of exercising options available to Kasinger.
CRISPR Therapeutics总法律顾问兼秘书詹姆斯·卡辛格于2024年2月20日完成了1,913股普通股的出售。该交易以每股79.67美元的价格执行，总市值为152,408.71美元。在此次出售之前，卡辛格于2024年2月18日通过行使衍生证券收购了3,825股股票。这些交易之后，卡辛格在CRISPR Therapeutics的直接持有量为57,371股普通股。此次出售是一项公开市场交易，此次收购是行使Kasinger可用期权的结果。
CRISPR Therapeutics总法律顾问兼秘书詹姆斯·卡辛格于2024年2月20日完成了1,913股普通股的出售。该交易以每股79.67美元的价格执行，总市值为152,408.71美元。在此次出售之前，卡辛格于2024年2月18日通过行使衍生证券收购了3,825股股票。这些交易之后，卡辛格在CRISPR Therapeutics的直接持有量为57,371股普通股。此次出售是一项公开市场交易，此次收购是行使Kasinger可用期权的结果。
有用
没用